Skip to main content

A hematologic clinical trial - LYC2

Testing if a high dose chemotherapy and infusion of the patients’ own stem cells improves survival in lymphoma patients
Disease Site
Hematologic Clinical Trials
Trial Code
LYC.2 ǀ NCT06724237
Trial Status
Open to patient enrollment

What is the purpose of this study?

This study will test a different treatment option for patients with peripheral T-cell lymphoma. The purpose of this study is to compare the usual chemotherapy alone to using high dose chemotherapy followed by a transplant of your own stem cells after completing the usual chemotherapy.

Why is this study important?

Treatment with high dose chemotherapy followed by a stem cell transplant could prevent your lymphoma from returning. This study aims to prove if this new treatment option is beneficial for peripheral T-cell lymphoma patients.

Who can participate in this study?

This trial is for people:

  • diagnosed with Peripheral T-cell lymphoma
  • between the ages of 18-75 years
  • finished their initial chemotherapy treatment
  • achieved complete remission following initial chemotherapy

This trial is not for:

  • people wanting to conceive a child during or shortly after receiving treatment from the study
  • people who are pregnant or currently breast feeding
What are the risks?
  • If you choose to take part in this study, there is a risk that the additional treatment of high dose chemotherapy and stem cell transplant may not be better than the standard treatment (no additional treatment after achieving remission). There is also a risk that you could have side effects from the high dose chemotherapy and stem cell transplant. Some of the most common side effects that the study doctors know about are: low blood counts; nausea and vomiting; permanent damage to organs; discomfort related to giving blood during the stem cell collection process; and a very small chance that the transplanted stem cells may not recover. You will find details of all side effects in the consent document.
What can I expect?
  • If you choose to take part in this study, you will be randomly placed in one of two groups. If you are placed in Group 1 you will not receive any treatment, which is the current standard of care. If you are placed in Group 2, you will receive high dose chemotherapy and a transplant of your own stem cells (the new treatment).

How can I find out more or join the study?

Talk to your cancer doctor if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you.

Before you join this study, you will be asked to review an Informed Consent document which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your standard medical care.

The LYC.2 study is currently enrolling patients at cancer centres in Canada. For a full list of participating cancer centres please visit www.clinicaltrials.gov and search using NCT06724237.

Use this trial information for your conversation with your health care team

Participating centres

Information coming soon.